View on Pubmed.gov 18723098 | View on doi.org 10.1016/j.vascn...
Influence of method of systemic administration of adenovirus on virus-mediated toxicity: focus on mortality, virus distribution, and drug metabolism.
- The University of Texas at Austin, College of Pharmacy, Division of Pharmaceutics, Austin, TX 78712-1074, USA.
Abstract
INTRODUCTION
Doses of 2 x 10(12) virus particles/kilogram (vp/kg) and higher of recombinant human adenovirus serotype 5 (HAdV-5) given via the tail vein induce significant toxicity and mortality in the rat. This was not observed when doses of 5.7 x 10(12) vp/kg were given through a surgically implanted jugular catheter. Here we assess how the manner by which HAdV-5 is introduced into the systemic circulation affects biodistribution, transgene expression, toxicity and mortality 0.25, 1, and 4 days after treatment in the rat. Animals were given 5.7 x 10(12) vp/kg of HAdV-5 expressing beta-galactosidase or saline through a jugular catheter or by direct tail vein injection.
RESULTS
All animals survived after jugular vein dosing. Tail vein injection of HAdV-5 increased the mortality rate to 42% (p< or =0.01). All deaths occurred within 4 h. Animals dosed through the jugular vein had significantly higher levels of transgene expression in the liver and spleen and significantly more viral genomes in these tissues and kidney and lung within the first 24 h of viral infection compared to those dosed by tail vein injection (p< or =0.01). There was no significant difference between the groups thereafter. Samples from animals that died contained even higher levels of viral genomes and serum transaminases were elevated on average by a factor of 4 at the time of death. There was no significant difference between the two dosing methods with respect to changes in hepatic cytochrome P450 expression and activity throughout the study.
CONCLUSION
These findings suggest that the method of systemic administration should be carefully considered when assessing toxicity data and other parameters at early time points after virus administration in the rat and possibly other animal models.
References
Fundam Appl Toxicol. 1986 Nov;7(4):658-63
J Pharm Sci. 1997 May;86(5):517-25
Drug Metab Dispos. 2008 Feb;36(2):205-16
Am J Physiol Regul Integr Comp Physiol. 2005 Nov;289(5):R1244-52
Cited by 10 citations (total)
Journal Article
Development of a New Hyaluronic Acid Based Redox-Responsive Nanohydrogel for the Encapsulation of Oncolytic Viruses for Cancer Immunotherapy.
Electronic publication date January 14, 2021
Siyuan Deng [...] Piera Di Martino et al.
Oncolytic viruses (OVs) are emerging as promising and potential anti-cancer therapeutic agents, not only able to kill cancer cells directly...
Journal Article
Heart-specific expression of the green fluorescent protein gene in avian embryos by administration of recombinant adenovirus type-5 vector into the embryonic blood vessel.
Electronic publication date October 14, 2024
Wonjun Choi [...] Kichoon Lee et al.
Genetic modification could provide direct functions of genes that could potentially contribute to diverse areas of research including genetics,...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
- •
Substances
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •